Early Detection of Cardiotoxicity During Sunitinib or Sorafenib Chemotherapy Using Cardiac Biomarkers.
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 18 Apr 2017
At a glance
- Drugs Sorafenib (Primary) ; Sunitinib (Primary)
- Indications Cancer
- Focus Adverse reactions; Biomarker; Pharmacogenomic
- 12 Apr 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Sep 2018.
- 08 Apr 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Sep 2017.
- 29 Mar 2013 Status changed from recruiting to active, no longer recruiting as reported by M.D. Anderson Cancer Center record.